

M&A MARKET MONITOR

MEDICAL TECHNOLOGY

January 2021


U.S. & Canada M&A Market Overview



Overall Market Transactions

Quick Highlights

- Although the pandemic affected the U.S. & Canada M&A market, volume and multiples ended the year at approximately 90% of recent historical averages
 - 2020 deal count was 88% of the previous 4-year (2016-2019) average
 - 2020 median TEV/LTM EBITDA multiple was 92% of the previous 4-year (2016-2019) average



Source: S&P Capital IQ; ArkMalibu; Other publicly available sources, As of 12/31/2020

About the Data

The information presented in this report is an analysis of deals in the United States or Canada. A deal is described as any closed or announced M&A transaction where the target is headquartered in the United States or Canada, financial terms of the transaction have been disclosed, and the target has an industry classification that falls into the subject industry group and as such may not be representative of your company's market valuation. Past performance is not indicative of future results. Certain adjustments have been made to the information to exclude transactions which are not specific to the industry or incorporate relevant transactions for which an industry classification was omitted.


U.S. & Canada M&A Market Overview

Medical Technology Transactions



Quick Highlights

- The Medical Technology industry 2020 deal count and multiples exceeded historical averages
 - 2020 deal count was 111% of the previous 4-year (2016-2019) average
 - 2020 median TEV/LTM EBITDA multiple was 113% of the previous 4-year (2016-2019) average



Source: S&P Capital IQ; ArkMalibu; Other publicly available sources

As of 12/31/2020

About the Data

The information presented in this report is an analysis of deals in the United States or Canada. A deal is described as any closed or announced M&A transaction where the target is headquartered in the United States or Canada, financial terms of the transaction have been disclosed, and the target has an industry classification that falls into the subject industry group and as such may not be representative of your company's market valuation. Past performance is not indicative of future results. Certain adjustments have been made to the information to exclude transactions which are not specific to the industry or incorporate relevant transactions for which an industry classification was omitted.

Public Companies' Trading Metrics | Medical Technology

As of: 12/31/2020

Category / Company	Valuation Statistics				Multiples Data			
	Last Price	Equity Value	Enterprise Value	EBITDA Margin	EV / Revenue (x)		EV / EBITDA (x)	
					LTM	NTM	LTM	NTM
USD in millions except per share price								
Biotechnology & Life Sciences								
Alexion Pharmaceuticals, Inc.	\$156.24	\$34,192	\$34,866	53.0%	5.9	5.4	11.2	9.4
Biogen Inc.	\$244.86	\$37,679	\$40,910	50.1%	2.9	3.7	5.7	7.9
Bio-Rad Laboratories, Inc.	\$582.94	\$17,345	\$16,836	19.3%	7.1	6.7	33.2	32.0
Eurofins Scientific SE	\$83.95	\$16,014	\$19,233	18.6%	3.3	2.9	15.9	12.4
Gilead Sciences, Inc.	\$58.26	\$73,031	\$75,312	27.4%	3.3	3.1	11.9	6.1
Illumina, Inc.	\$370.00	\$54,020	\$52,601	31.1%	16.2	14.2	48.7	46.1
IQVIA Holdings Inc.	\$179.17	\$34,352	\$46,130	16.2%	4.2	3.8	23.4	17.1
Lonza Group Ltd	\$642.89	\$47,760	\$51,521	27.7%	7.6	7.1	26.9	25.2
Mettler-Toledo International Inc.	\$1,139.68	\$27,118	\$28,192	27.3%	9.4	8.7	34.5	29.8
Regeneron Pharmaceuticals, Inc.	\$483.11	\$50,990	\$47,783	36.2%	5.2	4.8	14.3	12.6
Sartorius Stedim Biotech S.A.	\$356.21	\$32,835	\$32,994	30.0%	15.5	12.4	50.5	39.8
Vertex Pharmaceuticals Incorporated	\$236.34	\$61,457	\$55,853	46.4%	9.3	8.3	20.1	13.8
Waters Corporation	\$247.42	\$15,352	\$16,631	33.5%	7.2	6.9	20.6	21.4
Median	\$247.42	\$34,352	\$40,910	30.0%	7.1	6.7	20.6	17.1

Source: S&P Capital IQ; ArkMalibu

EV = enterprise value; LTM = last twelve months; NTM = next twelve months; NM = not meaningful

Public Companies' Trading Metrics | Medical Technology

As of: 12/31/2020

Category / Company	Valuation Statistics				Multiples Data			
	Last Price	Equity Value	Enterprise Value	EBITDA Margin	EV / Revenue (x)		EV / EBITDA (x)	
LTM					NTM	LTM	NTM	
USD in millions except per share price								
Medical Devices								
Abiomed, Inc.	\$324.20	\$14,651	\$13,926	30.9%	17.3	14.7	55.3	45.1
Align Technology, Inc.	\$534.38	\$42,136	\$41,607	18.4%	18.2	13.2	93.2	46.3
Baxter International Inc.	\$80.24	\$40,988	\$43,820	23.9%	3.8	3.7	14.8	16.4
Boston Scientific Corporation	\$35.95	\$51,478	\$59,048	21.0%	5.8	5.2	26.8	18.8
Coloplast A/S	\$152.77	\$32,492	\$32,683	34.8%	10.7	10.2	29.9	28.4
Edwards Lifesciences Corporation	\$91.23	\$56,859	\$56,254	32.1%	12.9	11.4	39.4	34.4
Hologic, Inc.	\$72.83	\$18,718	\$21,189	40.6%	5.6	4.2	13.6	8.3
IDEXX Laboratories, Inc.	\$499.87	\$42,639	\$43,454	28.3%	16.8	15.0	57.5	54.5
Intuitive Surgical, Inc.	\$818.10	\$96,172	\$91,417	30.0%	21.2	19.2	70.7	45.4
Olympus Corporation	\$21.86	\$28,108	\$29,614	18.4%	4.2	4.0	22.8	16.4
ResMed Inc.	\$212.56	\$30,803	\$31,571	32.2%	10.4	9.8	32.2	29.2
Smith & Nephew plc	\$20.62	\$18,043	\$20,582	20.4%	4.0	4.1	18.4	15.6
Stryker Corporation	\$245.04	\$92,084	\$98,460	27.1%	6.9	6.1	24.7	20.7
Sysmex Corporation	\$120.15	\$25,104	\$24,777	24.8%	8.8	8.3	36.7	31.3
Terumo Corporation	\$41.78	\$31,567	\$32,416	24.2%	5.5	5.2	23.0	20.5
Zimmer Biomet Holdings, Inc.	\$154.09	\$31,940	\$39,281	27.4%	5.6	4.9	20.3	15.1
Median	\$136.46	\$32,216	\$35,982	27.2%	7.9	7.2	28.3	24.6

Source: S&P Capital IQ; ArkMalibu

EV = enterprise value; LTM = last twelve months; NTM = next twelve months; NM = not meaningful

Public Companies' Trading Metrics | Medical Technology

As of: 12/31/2020

Category / Company	Valuation Statistics				Multiples Data			
	Last Price	Equity Value	Enterprise Value	EBITDA Margin	EV / Revenue (x)		EV / EBITDA (x)	
					LTM	NTM	LTM	NTM
USD in millions except per share price								
Healthcare Technology								
Allscripts Healthcare Solutions, Inc.	\$14.44	\$2,281	\$3,258	4.2%	1.9	2.1	29.0	12.1
Cerner Corporation	\$78.48	\$24,061	\$24,671	22.5%	4.4	4.4	19.2	13.5
Craneware plc	\$31.40	\$831	\$782	28.0%	9.9	10.6	33.8	30.2
Evolent Health, Inc.	\$16.03	\$1,351	\$1,359	-0.1%	1.4	1.4	49.0	34.9
HMS Holdings Corp.	\$36.75	\$3,254	\$3,302	18.4%	5.1	4.5	26.9	16.3
Inovalon Holdings, Inc.	\$18.17	\$2,824	\$3,744	27.4%	5.7	5.2	19.7	14.5
M3, Inc.	\$94.40	\$64,070	\$63,259	32.6%	45.2	36.0	139.7	103.3
NextGen Healthcare, Inc.	\$18.24	\$1,217	\$1,225	6.3%	2.2	2.2	27.8	12.5
Omniceil, Inc.	\$120.02	\$5,078	\$4,966	9.9%	5.6	5.0	48.7	25.0
Tabula Rasa HealthCare, Inc.	\$42.84	\$965	\$1,197	-3.6%	4.1	3.6	NM	37.4
Teladoc Health, Inc.	\$199.96	\$28,986	\$28,811	2.2%	33.2	16.1	NM	146.0
Veeva Systems Inc.	\$272.25	\$41,237	\$39,705	26.9%	28.8	24.1	103.4	62.5
Median	\$39.80	\$3,039	\$3,523	14.1%	5.4	4.7	31.4	27.6

Source: S&P Capital IQ; ArkMalibu

EV = enterprise value; LTM = last twelve months; NTM = next twelve months; NM = not meaningful

Public Companies' Trading Metrics | Medical Technology

As of: 12/31/2020

Category / Company	Valuation Statistics				Multiples Data			
	Last Price	Equity Value	Enterprise Value	EBITDA Margin	EV / Revenue (x)		EV / EBITDA (x)	
					LTM	NTM	LTM	NTM
USD in millions except per share price								
Diversified Medical Technology								
Abbott Laboratories	\$109.49	\$187,600	\$201,641	24.3%	6.3	5.2	25.8	18.2
AbbVie Inc.	\$107.15	\$189,171	\$268,325	45.2%	6.6	5.0	14.6	9.8
Agilent Technologies, Inc.	\$118.49	\$36,359	\$37,455	25.3%	7.0	6.5	26.5	24.7
Amgen Inc.	\$229.92	\$133,852	\$155,779	50.6%	6.2	5.9	12.3	9.8
Becton, Dickinson and Company	\$250.22	\$72,777	\$88,307	27.3%	5.2	4.6	18.4	15.6
Danaher Corporation	\$222.14	\$157,803	\$178,156	27.5%	8.7	7.2	30.6	24.1
Johnson & Johnson	\$157.38	\$414,310	\$421,287	33.7%	5.2	4.8	15.5	14.2
Koninklijke Philips N.V.	\$53.55	\$48,705	\$54,860	13.1%	2.3	2.3	15.8	12.0
Medtronic plc	\$117.14	\$157,673	\$173,529	23.5%	6.2	5.4	26.5	16.9
PerkinElmer, Inc.	\$143.50	\$16,068	\$17,839	26.3%	5.5	4.2	19.6	13.0
Roche Holding AG	\$349.25	\$298,665	\$313,770	38.6%	4.5	4.4	11.4	10.7
Siemens Healthineers AG	\$51.35	\$54,985	\$60,892	18.4%	3.4	3.2	18.7	15.1
Thermo Fisher Scientific Inc.	\$465.78	\$184,605	\$198,172	29.3%	7.0	5.9	23.7	18.0
Median	\$143.50	\$157,673	\$173,529	27.3%	6.2	5.0	18.7	15.1

Source: S&P Capital IQ; ArkMalibu

EV = enterprise value; LTM = last twelve months; NTM = next twelve months; NM = not meaningful



ARKMALIBU

| UNCONFLICTED. UNORTHODOX. UNRELENTING. |

ArkMalibu is one of the only Mergers & Acquisitions advisory firms that focuses exclusively on sell-side transactions.

We're not like other banks – we don't have conflicted business relationships with buyers, leaving our senior advisors and principals unhindered and unyielding in their pursuit of your goals. From the first meeting to dry ink, we are dedicated to exceeding your expectations and surpassing industry valuation benchmarks during one of life's most prodigious events. Selling a company requires both psychological intelligence and financial rigor, and that is ArkMalibu. We're a steady ship in stormy seas – here to guide you through uncharted territory with experience, integrity, and confidentiality at every turn.



Unconflicted. Loyalty to You is our Livelihood

- We only represent sellers; we're not incentivized to encourage you to accept less than your company's true maximum value.
- We pursue the highest possible value because we're unconflicted.



Unorthodox. Senior-Level Service is Our Standard

- All of ArkMalibu's clients receive care and attention from our senior-level advisors and principals.
- From analysts to principals, our team remains present and available throughout the process.



Unrelenting. Our Unrivaled Strategy Sells Your Story

- Our approach: understand, capture, and communicate your company's culture – the asset that can't be duplicated – and work to identify buyers whose goals and values align with yours, negotiating tirelessly on your behalf in order to complete the deal with the best partner.
- Our proprietary Four Boxes Analysis delivers prospective buyers a compelling investment story with undeniable upside.



We are Anchored to Increasing Your Value

- ArkMalibu is tied to your destiny; we are anchored to the goal of bringing you unparalleled value while navigating the personalities and interests of the people involved.
- Selling a business requires as much EQ as IQ; with our depth of experience and understanding of the complex human dynamics at play, we coach you through the challenges so you can enjoy your hard-earned and well-deserved prosperity.



4555 Lake Forest Drive, Suite 365
Cincinnati, OH 45242



(513) 583-5413



www.arkmalibu.com